Omar Amr S, Sudarsanan Suraj, Ewila Hesham, Kindawi Ali
Department of Cardiothoracic Surgery/Cardiac Anaesthesia & ICU Section, Heart Hospital, Hamad Medical Corporation, Doha PO: 3050 Doha, Qatar.
BMC Res Notes. 2014 Aug 15;7:535. doi: 10.1186/1756-0500-7-535.
Bleeding is a common complication after cardiac surgery. However, lower gastrointestinal bleeding is not usually associated with this type of surgery.
A 50-year-old man with a history of aortic regurgitation underwent elective mechanical valve replacement under cardiopulmonary bypass. He experienced a complicated intraoperative course involving unexplained cardiac arrest following induction of anesthesia. He also developed two episodes of massive lower gastrointestinal bleeding secondary to mucosal ischemia while convalescing in the cardiothoracic surgery intensive care unit. After unsuccessful attempts to control the bleeding, exhaustion of blood products, and consideration of the high risk of mortality associated with surgery and the possibility of early- and long-term surgical complications, the decision was made to administer two successive doses of recombinant activated factor VII at 60 mcg/kg. Hemostasis was achieved without adverse systemic or valvular effects.
A favorable outcome was achieved after administration of recombinant activated factor VII, which controlled the patient's severe lower gastrointestinal bleeding. This outcome suggests the need to raise awareness about the use of this drug in dire circumstances when other conventional measures fail or are unsuitable.
出血是心脏手术后常见的并发症。然而,下消化道出血通常与这类手术无关。
一名有主动脉瓣反流病史的50岁男性在体外循环下接受择期机械瓣膜置换术。他经历了复杂的术中过程,包括麻醉诱导后不明原因的心脏骤停。在心胸外科重症监护病房康复期间,他还出现了两次因黏膜缺血继发的大量下消化道出血。在控制出血的尝试失败、血液制品耗尽,且考虑到手术相关的高死亡风险以及早期和长期手术并发症的可能性后,决定连续两次给予60微克/千克的重组活化因子VII。出血得到控制,且未出现全身性或瓣膜性不良影响。
给予重组活化因子VII后取得了良好的效果,控制了患者严重的下消化道出血。这一结果表明,当其他常规措施失败或不适用时,需要提高对在危急情况下使用这种药物的认识。